scholarly journals The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias

2017 ◽  
Vol 77 (08) ◽  
pp. 887-893 ◽  
Author(s):  
Kristin Friebe ◽  
Rüdiger Klapdor ◽  
Peter Hillemanns ◽  
Matthias Jentschke
Keyword(s):  
Intraepithelial Neoplasia ◽  
Hpv Testing ◽  
Hpv 16 ◽  
Hybrid Capture ◽  
Recurrence Prediction ◽  
Hpv Status ◽  
Hpv Test ◽  
Hybrid Capture 2 ◽  
High Risk Hpv

Abstract Introduction In this retrospective study partial genotyping of human papilloma viruses (HPV) using the Abbott RealTime HighRisk HPV Test (RealTime) was compared with simple HPV detection (Qiagen Hybrid Capture 2 Test; hc2) for recurrence prediction at the first follow-up examination after conization of cervical intraepithelial neoplasia (CIN). Methods 144 women who had undergone conization for CIN between January 2007 and December 2013 were included. HPV status was determined preoperatively and at first follow-up using hc2 in 103 women and RealTime in 41 women. Recurrent or persistent CIN was assumed when CIN2+ was confirmed histologically or on comparable cytology findings. Results Of the 144 women with complete data 12 (8.3%) had a recurrence after conization. HPV persistence at follow-up correlated significantly with recurrence (hc2: p = 0.003; RealTime: p = 0.003) and both sensitivity and specificity were high (hc2 = 100 and 78.4% respectively; RealTime = 75.0 and 83.9%). Whereas isolated HPV testing had a relatively low positive predictive value for recurrence (hc2 16%; RealTime 54.5%), this rose to 80% with HPV 16 detection at follow-up. Conclusion At follow-up after conization of CIN the combination of high risk HPV detection and partial genotyping of HPV 16 constitutes excellent diagnostic criteria for recurrence/persistence of CIN.

Prevalence of HPV 16/18 genotypes and histopathologic follow-up outcomes in women with negative cytology and positive high-risk HPV test results

2015 ◽  
Vol 4 (5) ◽  
pp. 261-266 ◽  
Author(s):  
Anna Woodard ◽  
R. Marshall Austin ◽  
Zaibo Li ◽  
Joseph Beere ◽  
Chengquan Zhao
Keyword(s):  
High Risk ◽  
Test Results ◽  
Hpv 16 ◽  
Hpv Test ◽  
High Risk Hpv

scholarly journals Comparison of Clinical Performance of Abbott RealTime High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting

2011 ◽  
Vol 49 (4) ◽  
pp. 1446-1451 ◽  
Author(s):  
F. M. Carozzi ◽  
E. Burroni ◽  
S. Bisanzi ◽  
D. Puliti ◽  
M. Confortini ◽  
...  
Keyword(s):  
High Risk ◽  
Clinical Performance ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Hybrid Capture 2 ◽  
High Risk Hpv

scholarly journals Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population

2019 ◽  
Vol 57 (12) ◽  
Author(s):  
Oscar G. W. Wong ◽  
Idy F. Y. Ng ◽  
Obe K. L. Tsun ◽  
Herbert H. Pang ◽  
Philip P. C. Ip ◽  
...  
Keyword(s):  
Machine Learning ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Squamous Cells ◽  
Archived Samples ◽  
Hpv Test ◽  
Screening Population ◽  
High Risk Hpv

ABSTRACT This study aimed (i) to compare the performance of the BD Onclarity human papillomavirus (HPV) assay with the Cobas HPV test in identifying cervical intraepithelial neoplasia 2/3 or above (CIN2/3+) in an Asian screening population and (ii) to explore improving the cervical cancer detection specificity of Onclarity by machine learning. We tested 605 stratified random archived samples of cervical liquid-based cytology samples with both assays. All samples had biopsy diagnosis or repeated negative cytology follow-up. Association rule mining (ARM) was employed to discover coinfection likely to give rise to CIN2/3+. Outcome classifiers interpreting the extended genotyping results of Onclarity were built with different underlying models. The sensitivities (Onclarity, 96.32%; Cobas, 95.71%) and specificities (Onclarity, 46.38%; Cobas, 45.25%) of the high-risk HPV (hrHPV) components of the two tests were not significantly different. When HPV16 and HPV18 were used to further interpret hrHPV-positive cases, Onclarity displayed significantly higher specificity (Onclarity, 87.10%; Cobas, 80.77%). Both hrHPV tests achieved the same sensitivities (Onclarity, 90.91%; Cobas, 90.91%) and similar specificities (Onclarity, 48.46%; Cobas, 51.98%) when used for triaging atypical squamous cells of undetermined significance. Positivity in both HPV16 and HPV33/58 of the Onclarity channels entails the highest probability of developing CIN2/3+. Incorporating other hrHPVs into the outcome classifiers improved the specificity of identifying CIN2/3 to up to 94.32%. The extended genotyping of Onclarity therefore can help to highlight patients having the highest risk of developing CIN2/3+, with the potential to reduce unnecessary colposcopy and negative psychosocial impact on women receiving the reports.

scholarly journals A Population-Based Clinical Trial Comparing Endocervical High-Risk HPV Testing Using Hybrid Capture 2 and Cervista From the SHENCCAST II Study

2011 ◽  
Vol 135 (5) ◽  
pp. 790-795 ◽  
Author(s):  
Jerome L. Belinson ◽  
Ruifang Wu ◽  
Suzanne E. Belinson ◽  
Xinfeng Qu ◽  
Bin Yang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
High Risk ◽  
Population Based ◽  
Hpv Testing ◽  
Hybrid Capture ◽  
Hybrid Capture 2 ◽  
High Risk Hpv

scholarly journals Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia

2001 ◽  
Vol 84 (6) ◽  
pp. 796-801 ◽  
Author(s):  
M A E Nobbenhuis ◽  
C J L M Meijer ◽  
A J C van den Brule ◽  
L Rozendaal ◽  
F J Voorhorst ◽  
...  
Keyword(s):  
High Risk ◽  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
Hpv Testing ◽  
High Risk Hpv ◽  
Current Guidelines

Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study

2013 ◽  
Vol 58 (1) ◽  
pp. 161-167 ◽  
Author(s):  
Arundhati Rao ◽  
Maria Teresa Sandri ◽  
Mario Sideri ◽  
Stephen Young ◽  
Abha Sharma ◽  
...  
Keyword(s):  
High Risk ◽  
Test Results ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Hybrid Capture 2 ◽  
High Risk Hpv

scholarly journals Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany

2018 ◽  
Vol 57 (1) ◽  
Author(s):  
Thomas Iftner ◽  
Klaus-Joachim Neis ◽  
Alejandra Castanon ◽  
Rebecca Landy ◽  
Barbara Holz ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Clinical Performance ◽  
Absolute Risk ◽  
Intraepithelial Neoplasia ◽  
Cross Sectional ◽  
Predictive Values ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Hybrid Capture 2 ◽  
The Absolute

ABSTRACT Longitudinal data on the E6/E7 mRNA-based Aptima human papillomavirus (AHPV) assay exceeding three years in comparison to the gold standard Digene Hybrid Capture 2 (HC2) test are not available. We previously reported the cross-sectional data of the German AHPV Screening Trial (GAST) in which 10,040 women were recruited and tested by liquid-based cytology, the HC2 assay, and the AHPV assay. Four hundred eleven test-positive women were followed for up to six years. In addition, 3,295 triple-negative women were screened after a median time of six years. Overall, 28 high-grade cervical intraepithelial neoplasia (CIN3) cases were detected. The absolute risk of developing high-risk HPV-positive CIN3+ over six years among those women that tested negative at baseline was 2.2 (95% confidence interval [95% CI], 1.0 to 4.9) and 3.1 (95% CI, 1.7 to 5.7) per 1,000 women screened by the HC2 and the AHPV tests; the additional risk for those with AHPV-negative compared with HC2-negative results was 0.9 (95% CI, −0.2 to 2.1) per 1,000. In comparison, the absolute risk following a negative LBC test was 9.3 (95% CI, 2.9 to 30.2). The relative sensitivity of AHPV compared to HC2 was 91.5% for CIN3+, and the negative predictive values were 99.8% (95% CI, 99.5 to 99.9%) for HC2 and 99.7% (95% CI, 99.4 to 99.8%) for AHPV. Our data show that the longitudinal performance of the AHPV test over six years is comparable to the performance of the HC2 test and that the absolute risk of CIN3+ over six years following a negative AHPV result in a screening population is low. (This study is registered at ClinicalTrials.gov under registration number NCT02634190.)

scholarly journals Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany

2015 ◽  
Vol 53 (8) ◽  
pp. 2509-2516 ◽  
Author(s):  
Thomas Iftner ◽  
Sven Becker ◽  
Klaus-Joachim Neis ◽  
Alejandra Castanon ◽  
Angelika Iftner ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Precancerous Lesions ◽  
Cervical Screening ◽  
Intraepithelial Neoplasia ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
Hybrid Capture ◽  
Test Characteristics ◽  
Hpv Test ◽  
Screening Population ◽  
Hybrid Capture 2

Testing for E6/E7 mRNA in cells infected with high-risk (HR) human papillomavirus (HPV) might improve the specificity of HPV testing for the identification of cervical precancerous lesions. Here we compared the RNA-based Aptima HPV (AHPV) assay (Hologic) and the DNA-based Hybrid Capture 2 (HC2) HPV test (Qiagen) to liquid-based cytology (LBC) for women undergoing routine cervical screening. A total of 10,040 women, 30 to 60 years of age, were invited to participate in the study, 9,451 of whom were included in the analysis. Specimens were tested centrally by LBC, the AHPV test, and the HC2 test, and women who tested positive on any test were referred for colposcopy. Genotyping was performed on all HR-HPV-positive samples. Test characteristics were calculated based on histological review. As a result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), including 43 women with CIN3+. Sensitivity differences between the AHPV test and the HC2 test in detecting CIN2+ ( P = 0.180) or CIN3+ ( P = 0.0625) lesions were statistically nonsignificant. Of three CIN3 cases that were missed with the AHPV test, two cases presented lesion-free cones and one had a non-HR HPV67 infection. The specificity (<CIN2) and positive predictive value (CIN2+) of the AHPV test were significantly higher (both P < 0.001) than those of the HC2 test. The overall agreement between the tests was substantial (κ = 0.77). Finally, we present results for several possible triage strategies, based on the primary screening test being either the AHPV test or the HC2 test. In summary, the AHPV assay is both specific and sensitive for the detection of high-grade precancerous lesions and may be used in primary cervical cancer screening for women ≥30 years of age.

scholarly journals Risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990–1992, a 30-year follow-up study

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Marit Østlyngen Riibe ◽  
Sveinung Wergeland Sørbye ◽  
Gunnar Skov Simonsen ◽  
Arnfinn Sundsfjord ◽  
Josef Ekgren ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
University Hospital ◽  
First Year ◽  
Hpv 16 ◽  
Study Objective ◽  
Negative Test ◽  
Hpv Status ◽  
Hpv Test

Abstract Background/objective Having a 30-year follow-up of a cohort of women tested for HPV is a unique opportunity to further study long-term risk of CIN3+. The study objective was to compare HPV status at baseline with the risk of CIN3+ in the follow-up period of 30 years. Methods All women (n = 642) referred to the HPV outpatient clinic at the University Hospital of North Norway (UNN) in 1990–1992, with an HPV test at baseline, were included in a prospective cohort. HPV-testing was performed by two different HPV-DNA tests, and genotypes 6, 11, 16, 18, 31 and 33 were identified. High-risk (HR) HPV genotypes (16, 18, 31 and 33) were classified as HPV positive, whereas low-risk (LR) genotypes (6 and 11) in addition to absent HPV were classified as HPV negative. A single cohort in which women were classified for their HPV status underwent follow-up prospectively to the last time-point of observation of 30 years. Results During follow-up, 148 (148/642) cases of CIN3+ were detected, of whom 70.3% (104/148) were HPV positive and 29.7% (44/148) were HPV negative at baseline. The proportions of women who developed CIN3+ following a positive and a negative test were 46.6% (104/223) and 10.5% (44/419), respectively. Most cases of CIN3+ were seen shortly after the baseline HPV test, with 112 cases of CIN3+ diagnosed within the first year. In total, 48.6% (72/148) with HPV 16 and 57.6% (19/33) with HPV 33 developed CIN3+. Within the first year, CIN3+ was detected in 37.8% (56/148) with HPV 16, and 51.5% (17/33) with HPV 33. The long-term risk of CIN3+ was significantly lower than the short-term risk, and mainly associated with HPV 16. Overall, eight cases of cervical cancer were detected. Five were HPV positive, harboured HPV 16 at baseline and developed cervical cancer after 3, 4, 5, 11 and 24 years of follow-up. Conclusion and consequences HPV status at baseline is predictive for the subsequent risk of developing CIN3+. Women with a positive HPV test in 1990–1992 had a significantly higher risk of CIN3+ during 30 years of follow-up than those with a negative test. HPV 16 was associated with the greatest long-term risk of cervical cancer. All patients with a positive HPV test at baseline should be followed up until negative. Trial registration ISRCTN, ISRCTN10836802. Registered 14 December 2020 - Retrospectively registered.

Sign in / Sign up

Export Citation Format

Share Document